Project Grant R21AI182702
Award Date
12/19/24
Completion Date
11/30/26
Dollars Obligated
$184K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Cleveland Clinic Lerner College Of Medicine Of Case Western Reserve University (M5QFLTCTSQN6)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44195, USA
Similar Awards
This federal Project Grant award of $791,864 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify molecular factors controlling chromatin organization and gene regulation in the malaria parasite Plasmodium falciparum. The research aims to elucidate the importance of long non-coding RNAs (lncRNAs) in parasite development, virulence, and sexual differentiation, with the goal...
This $147,656 federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand the role of transmembrane proteins in the cell division process of the malaria parasite Plasmodium falciparum. The award, effective January 22, 2025 through October 31, 2027, will enable the integration of biochemical and super-resolution microscopy approaches to decipher...
This $516,175 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to evaluate the impact of pre-existing humoral immunity on hepatocyte death and its implications for malaria vaccine development. The grant, awarded to Seattle Children's Hospital's research institute, will fund a 2-year project exploring how non-neutralizing antibodies may promote apoptosis in...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) will support research to define the immune response to Plasmodium vaccination and test an adjuvant to boost immunity against malaria. The $205,125 award to the Hennepin Healthcare Research Institute will utilize an improved small animal model to compare vaccine responses in specific pathogen-free (SPF) mice versus...
This Project Grant award of $375,000.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports a research project to investigate the role of messenger ribonucleoprotein (mRNP) granules in regulating RNA metabolism and translation in the malaria parasite Plasmodium falciparum. The project aims to identify molecular markers for distinct mRNP types, determine their protein and mRNA compositions, and characterize their...
The federal Project Grant award of $459,131, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports research to identify essential functions of the mitochondrion in malaria parasites. The goal is to uncover novel drug targets within the parasite mitochondrion that could lead to the development of new antimalarial treatments effective against both symptomatic and transmission stages of malaria...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $244,440.00 to Albert Einstein College of Medicine to conduct research on the role of cytolytic ZEB2+ memory CD4+ T cells in protection against liver stage malaria. The research aims to gain insights into the cellular immune determinants associated with natural clinical immunity to malaria, in order to inform the development of more effective...
This Federal Project Grant award of $131,154 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research by Yale University to quantify functional immune responses against Plasmodium falciparum, the parasite that causes malaria. The research objectives are to: 1) Assess mechanisms of protective blood-stage immune responses, including neutralization and opsonic phagocytosis, and 2) Understand how merozoite antigenic...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $520,809 in funding to Rosalind Franklin University of Medicine & Science over the period from September 5, 2024 to August 31, 2029. The overarching goal of this research project is to investigate the role of TAM receptors in modulating the humoral immune response against parasitic infections, such as malaria....
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $206,116 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Oregon Health & Science University (OHSU) to develop novel 4-aminoquinoline compounds as therapeutics against multi-drug resistant Plasmodium falciparum, the deadliest species of malaria parasite. The project aims to further develop a compound, MH02-060, that has shown enhanced metabolic stability and in vivo efficacy...